在最近召开的一次会议上,研究人员对血吸虫病疫苗的研究和发展进行了评论,并一致认为接种疫苗预防人类血吸虫感染是可达到的目标。人们普遍认为,用环吡异喹酮(Praziqu-antel)控制血吸虫非常有效,因而不需进一步的检测。但这种看法受到了有力地冲击,因为用药后很快发生再感染。尤其是儿童,最易感染寄生虫。因此,必须进行多次治疗,从而增加了治疗费用,使这种用药控制治疗方法失去了吸引力。此外,曾有文章记录血吸虫对较早的药物羟氨喹(Oxamniquine)有抗药性,而且在目前的情况下对环吡异喹酮有抗药性的寄 At a recent meeting, researchers commented on the research and development of schistosomiasis vaccines and agreed that vaccination to prevent human schistosomiasis is a viable goal. It is generally accepted that the control of schistosomiasis with praziquantel is very effective and therefore requires no further testing. However, this view has been strongly influenced by the fact that re-infection occurs soon after treatment. Especially children, most susceptible to parasites. As a result, multiple treatments must be performed, thereby increasing the cost of treatment and rendering this drug-controlled treatment less attractive. In addition, there was an article documenting that Schistosoma japonicum is resistant to the earlier drug Oxamniquine and is, in the present case, resistant to cyclosporine